

Marc S. Raab is a physician-scientist and Professor of Medicine at the Heidelberg University Medical Center (HUMC) and a Group Leader at the German Cancer Research Center (DKFZ). He trained in internal medicine and then specialized in hematology/oncology before spending more than three years as a postdoctoral fellow at the Dana-Farber Cancer Institute, Harvard Medical School, in Boston. He returned to Heidelberg as an attending physician in 2008 and his main research focus is on translational research and early clinical trials. In 2010, he was appointed head of the Max-Eder Unit - 'Experimental Therapies for Hematologic Malignancies' - at the German Cancer Research Center (DKFZ). He is also Clinical Director of the Multiple Myeloma Center in Heidelberg and Head of the associated early clinical trial program. His current scientific focus is on exploring new avenues for targeted therapies as well as resistance mechanisms in refractory myeloma to facilitate personalized treatment approaches for these patients.